A b s t r a c t
Proteomic profiling with protein-chip technology has been used successfully to discover biomarkers with potential clinical usefulness in several cancer types. Little proteomic study has been done in B-cell lymphomas. We determined whether the expression of a set of proteins by protein-chip technology coupled with new informatics tools could be used to build a model to molecularly classify B-cell lymphoma subgroups. We used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to analyze 18 CD10+ B-cell lymphomas, including 6 grade 1 (G1) follicular lymphomas (FLs), 7 grade 3 (G3)
In recent years, a number of proteomic profiling studies examining prostate, 1 breast, 2,3 ovarian, 4 bladder, 5 lung, 6 and hepatocellular 7 carcinoma have been conducted. These studies identified specific protein biomarkers that can distinguish patients with a particular type of cancer from patients without cancer by using a new protein-chip technology called surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS, Ciphergen Biosystems, Fremont, CA). Compared with traditional 2-dimensional (2D) gel analysis, SELDI-TOF-MS has 2 major advantages in clinical research applications: it requires much less sample and is much more rapid.
To date, reports of analysis of malignant lymphomas by this new protein-chip technology have been limited. As a group, the B-cell lymphomas are the most common lymphoproliferative disorders in the Western world. 8 The B-cell lymphomas are a heterogeneous group of diseases, ranging from low-to high-grade lesions, and are characteristically subjected to various immunologic and molecular tests for identification of characteristic immunophenotypic and genetic profiles for accurate subclassification. However, the prognosis for apparently homogeneous patients with a given subtype of Bcell lymphomas is variable. For example, in the follicular lymphoma (FL) subgroup, some patients have disease that is refractory to current therapies and progresses rapidly to highgrade B-cell lymphoma, whereas in other patients, the disease responds rapidly to therapy and the patients live for many years with little or no detectable disease. 9 The outcomes of lymphomas are affected by many factors, including tumor clones, host conditions, and treatment regimens. Proteomic study might provide more information about specific tumor clones for different patients at the protein level, which could lead to further understanding of the biology of lymphoma.
Analysis of RNA and complementary DNA on chip microarrays has allowed global gene expression profiling of many lymphoma subtypes. [10] [11] [12] The application of gene expression profiling techniques and associated bioinformatics tools has fueled an unprecedented expansion of knowledge about these tumors in a short time. Many new candidate genes that might have important roles in lymphoma development, prognosis, progression, and treatment have been identified. However, all of this new information ultimately must be validated by evaluation of proteins, the actual gene products.
Proteins that are altered by the disease process may change in a variety of ways, such as protein synthesis, protein degradation, or posttranslational modifications. There often is no correlation between gene expression (messenger RNA) levels and protein expression levels, so messenger RNA and protein expression must be evaluated before the control of gene networks can be understood fully. Regulation of many physiologic processes is posttranscriptional, so evaluation of the proteome is essential. We hypothesized that the proteomic analysis of groups or clusters of proteins would allow comparison of protein expression profiles among the different B-cell lymphomas. Unique groups of proteins could be used not only to explore mechanisms of lymphomagenesis but also as prognostic markers, risk factors for transformation, and potential key effectors in biotherapy.
We report the results of our application of protein-chip technology to the analysis of reactive follicular hyperplasia and CD10+ mature B-cell lymphomas, including FL and Burkitt lymphoma (BL). We selected these diseases because they are CD10+ mature B-cell lesions that differ from each other in genetics, morphologic features, and clinical behavior.
Reactive follicular hyperplasia is the benign counterpart of FL. FL is classified as a low-grade B-cell lymphoma because it is characterized by an indolent clinical course. 13 In comparison, BL is a high-grade B-cell lymphoma that results in rapid patient demise without aggressive chemotherapy. 14 Although FL and BL share similarity in immunophenotype (positive for CD10, CD19, CD20, and monoclonal surface immunoglobulin light chain), they also show different antigen expression for bcl-2, bcl-6, and others. In addition, FL presents heterogeneous clinical behaviors. In about 25% of FL cases, there is a progression over time from low-to highgrade lymphoma. 15 Histologically, the grade of the FL is based on the number of large cells. CD10+ mature B-cell lesions seem to be a good disease model for proteomic analysis to see the differential protein expression among benign conditions, low-grade lymphomas, and high-grade lymphomas and to study protein expression potentially associated with disease progression.
This study was conducted to test whether unique protein expression signatures could be generated from clinical samples of these different B-cell lymphomas by protein-chip technology coupled with bioinformatics tools. Our results demonstrated that SELDI-TOF-MS indeed can generate protein expression profiles from clinical B-cell lymphoma samples that can distinguish different subtypes of reactive and neoplastic CD10+ lymphoproliferations. Furthermore, the protein signatures were able to differentiate grade 1 (G1) from grade 3 (G3) FL. Although preliminary, these protein profiling results in CD10+ B-cell lymphomas and benign reactive follicular hyperplasia offer new promise in the biologic investigation of lymphomas, including the potential not only to more accurately subclassify these lesions for more individualized therapeutic approaches but also to provide new insights into the mechanisms of development, drug responsiveness, and progression of these tumors.
Materials and Methods

Clinical Samples
Frozen tissue samples with confirmed diagnoses of reactive follicular hyperplasia (n = 7), G1 FL (n = 6), G3 FL (n = 7), and BL (n = 5) were obtained from the tumor banks of the Hematopathology Division, Department of Pathology, Oregon Health and Sciences University, Portland. All cases were well characterized with necessary immunohistochemical stains and flow cytometric analysis. The immunophenotype of each lymphoma is given in ❚Table 1❚. All BL cases were confirmed with fluorescence in situ hybridization or conventional cytogenetics for t (8;14) .
Tissue Preparation
For sample preparation, 50 to 100 mg of frozen tissue samples were homogenized and lysed in 1 mL of TRI Reagent (Molecular Research Center, Cincinnati, OH). RNA and protein were extracted following the TRI Reagent protocol. To redissolve the protein pellet, 100 µL of 8 mol/L of urea/40 mmol/L of tris(hydroxymethyl)aminomethane (Tris), pH 7.4, solution was added. After 20 minutes of incubation at room temperature, samples were mixed thoroughly and centrifuged at 12,000g for 5 minutes at 4°C to form pellets of the undissolved material. The soluble protein concentrations were determined by using the Micro BCA protein assay kit (Pierce, Rockford, IL). The protein lysates were diluted to a final concentration of 2 µg/µL and stored at -80°C.
SELDI Analysis
The SELDI ProteinChip (Ciphergen Biosystems) analysis process is illustrated as ❚Figure 1❚. SAX2 strong anion exchange chips that bind negatively charged proteins and 96-well bioprocessors (Ciphergen Biosystems) were used for the analysis.
We used 40 mmol/L of sodium acetate, pH 5, as a binding buffer. The spots were washed twice at room temperature for 5 minutes with the binding buffer. Samples were diluted to a volume of 50 µL (0.26 µg/µL) in binding buffer. The samples then were placed on the arrays and incubated for 1 hour at room temperature while continuously being shaken. The samples were removed and the spots washed 3 times (5 minutes each) in binding buffer and then once quickly in water. The spots were air dried. We then applied 0.5 µL of 20% α-cyano-4-hydroxy-cinnamic acid (CHCA) matrix to each spot and allowed it to dry; then a second application of 0.5 µL of CHCA to each spot was done. To test reproducibility of the analysis, duplicate protein samples were used. Mass spectra were generated on a SELDI Protein Biology System II mass spectrometer (Ciphergen Biosystems). The significantly differentially expressed protein peaks were identified with the Mann-Whitney test (Ciphergen Biosystems ProteinChip Software, version 3.0), which compares peak intensities among the subtypes of lymphomas. The peaks with a P value of less than .05 were considered as significantly differentially expressed protein peaks.
Two-Way Hierarchical Clustering Analysis
For cluster analysis, the relative peak intensities were used. The relative peak intensities were calculated as follows: the peak intensity from each sample was divided by the mean intensity of all samples in the study regardless of diagnosis. The relative peak intensities were analyzed with 2-way hierarchical clustering using GeneMaths clustering software, version 1.5 (Applied Maths, Austin, TX). The color range generated is a reflection of the degrees of deviations from the mean. If a protein's expression is greater than the mean, it will be seen as red in the graph, and if it is less than the mean, it will be shown as green. The greater the difference from the mean, the more intense the color in the cluster plot.
Protein Identification
We separated 100 µg of protein on a tris-tricine gel as described. 16 Specific bands were excised from the gel and digested by the following steps. First, 100 µL of 25 mmol/L of ammonium bicarbonate (NH 4 HCO 3 ), 5% acetonitrile (ACN) solution was added and incubated for 30 minutes at room temperature. The solution was removed and the plate incubated in 25 mmol/L of NH 4 HCO 3 , 50% ACN solution for 30 minutes at room temperature. This step was repeated. The solution was removed and 100 µL of 100% ACN added and incubated at room temperature for 10 minutes. The ACN was removed and the plate put in a SpeedVac for 10 minutes. Then, 15 µL of trypsin (11 µg/mL in 25 mmol/L of NH 4 HCO 3 ) was added and the plate incubated at 37°C for 3 hours. Next, 8 µL of ACN was added and incubated for 15 minutes at 37°C. We then added 130 µL of 0.2% trifluoroacetic acid (TFA) to each well, and this was incubated for 30 minutes at room temperature. We added 3 µL of ACN to each column of the Zip plate. The trypsin digests were transferred from the digest plate to the Zip plate columns and vacuumed through the columns. The columns then were washed 2 times in 100 µL of 0.1% TFA, and the peptides were eluted from the columns using 10 µL of 50% ACN/0.1% TFA solution. The eluate was centrifuged at 3,000 rpm for 15 seconds and collected into clean 96-well plates. The samples were spotted onto a 96-spot matrix-assisted laser desorption/ionization (MALDI) plate and air dried. Then, 1 µL of 20% CHCA solution was spotted onto each spot and air dried. The plates were placed into the MALDI source. Mass spectrometry/mass spectrometry (MS/MS) spectra were acquired in an automated manner using standard ThermoFinnigan LCQ and analyzed further using SEQUEST software.
Results
Unique Protein Expression Spectra Can Distinguish Different Types and Grades of CD10+ B-Cell Lesions
A unique and reproducible protein expression profile was identified for reactive follicular hyperplasia (n = 7), FL (n = 13), and BL (n = 5) when the proteomic profiles of their cell lysates were analyzed on SAX2 anion exchange chips (pH 5.0) and the profiles were compared. A total of 71 individual Protein lysate extracted from frozen sample is loaded on a SAX2 ionic protein chip. The chip is inserted into the SELDI detector. The laser energy is used to activate proteins on the chip surface. The energy from the laser causes the proteins to fly off the surface through a vacuum tube to the detector. The time it takes a protein to reach the detector is proportional to its mass-tochange ratio (M/Z). A protein is represented as a peak in a spectrum. Ciphergen Biosystems software provides 3 formats of data: straight spectrum, synthetic gel view, and peak map. TOF-MS, time-of-flight mass spectrometry.
peaks were detected. ❚Figure 2❚ shows representative protein expression spectra (6 cases) for all 3 categories of B-cell lesions analyzed.
To determine whether protein spectra could reliably differentiate reactive follicular hyperplasia from B-cell lymphoma (including all FLs and BLs), the reactive follicular hyperplasia spectra were compared with all B-cell lymphoma spectra. This comparison identified 7 peaks that showed significant differences; 5 peaks were expressed at higher levels and 2 peaks at lower levels in reactive follicular hyperplasia than in the B-cell lymphomas. These peaks are shown in ❚Figure 3❚, and the mass-to-change ratio (M/Z) values of the peaks are given in ❚Table 2❚.
The spectra of all FLs and BLs also were analyzed and compared. There were 18 differentially expressed proteins detected that distinguished between these 2 B-cell lymphoma subtypes; 12 peaks were higher and 6 peaks lower in BL than in FL. These peaks are shown in ❚Figure 4❚, and the M/Z values of peaks for this comparison are given in ❚Table 3❚.
To detect proteins that might be involved in FL progression, we compared the protein expression spectra of G1 and G3 FLs. Five differentially expressed proteins (P < .05) were detected ❚Figure 5❚; 3 proteins (5,646, 11,300, and 14,000 d) were down-regulated, and 2 proteins (5,404 and 8,219 d) were up-regulated in G3 FL.
Detection of Differentially Expressed Protein Clusters With 2-Way Hierarchical Clustering Analysis
We next questioned whether these protein expression data could be analyzed by the same type of bioinformatics methods that were designed initially for the analysis of gene expression profiling data. To test the possibility of using these bioinformatics tools to analyze protein expression data, the patterns of differentially expressed protein peaks expressed for all 3 groups were analyzed using GeneMaths clustering software. Based on the 30 significantly different protein peaks among all samples, 5 of 7 reactive follicular hyperplasias, 5 of 5 BLs, and 14 of 16 FLs were placed in the proper diagnostic categories by 2-way hierarchical clustering analysis ❚Figure 6❚. Among all protein peaks, 5 clusters represented distinctive expression patterns. Cluster 1 was highly expressed only in reactive follicular hyperplasias, whereas cluster 2 was highly expressed only in FLs. Cluster 3, in contrast, was highly expressed in FLs ❚Figure 2❚ Protein expression spectra of reactive follicular hyperplasia (RFH), follicular lymphoma (FL), and Burkitt lymphoma (BL).
❚Figure 3❚ Comparison of reactive follicular hyperplasia (RFH) and B-cell lymphoma (BCL). The differentially expressed protein peaks are marked in red for representative spectra from RFH and BCL.
and BLs. Cluster 4 showed a high level of expression in BLs only, and cluster 5 revealed higher expression levels in most reactive follicular hyperplasias and BLs. Protein cluster analysis also could be used to identify FL progression and to separate G1 ❚Figure 7A❚ from G3 ❚Figure 7B❚ FL. In addition, by 2-way hierarchical clustering analysis, each individual lymphoma was found to have a unique protein expression pattern, even among the same subtype and same grade of B-cell lymphoma.
Protein Identification
In an attempt to identify the most differentially expressed protein, a tris-tricine electrophoresis gel was run. It revealed a differentially expressed protein at about 11,000 d, which was more abundant in G1 than in G3 ❚Figure 8❚ FL. The same expression pattern was shown previously by SELDI ( Figure  5 ). The 11,000-d bands were excised from each lane and digested with trypsin. The protein was identified as histone H4 (molecular weight, 11,280 d) using MALDI MS/MS. 
Discussion
The diagnosis and treatment of B-cell lymphomas is based on morphologic, immunologic, and cytogenetic findings. Protein markers have an important role in diagnosis, prognosis, and treatment planning, so it is obvious that an analysis of the global protein expression of B-cell lymphomas could provide valuable insights to diagnose and combat lymphomas. However, traditionally, proteomic studies have been carried out using cumbersome, labor-intensive 2D gel electrophoresis methods; the limitations of these methods have precluded their application to routine tumor analysis.
In recent years, revolutionary protein-chip technology has become available to help overcome these limitations. In conjunction with bioinformatics tools, protein-chip technology has been used successfully in biomarker discovery. Compared with 2D gel analysis, SELDI-TOF-MS is less labor-intensive, requires much less sample, and is better at resolving proteins smaller than 25 kd. Computerized protein profiling analysis relies on the pattern of protein expression rather than depending on the identification of every differentially expressed protein. This method provides a unique tool for analysis of B-cell lymphomas and lymphoid hyperplasias.
To our knowledge, this is the first study applying SELDI-TOF technology coupled with 2-way hierarchical cluster mapping to the analysis of clinical lymphoma tissue samples. Our study demonstrates that there are unique protein expression profiles for reactive follicular hyperplasias, FLs, and BLs. Certain sets of proteins were underexpressed or overexpressed in each diagnostic category.
We also demonstrated the value of the cluster analysis to protein-chip profiling, a process similar to the bioinformatics tools used for gene expression profiling. Protein signatures were identified and could be used to differentiate the types of CD10+ B-cell lesions studied. A unique protein expression pattern was identified for each subgroup, allowing the correct classification of each B-cell lesion by the specific protein profile on the SELDI ProteinChip. Cluster mapping also revealed distinct, individualized protein profiles for each lymphoma studied. This protein expression pattern theoretically could be used for fingerprinting each individual lymphoma. The biologic variations in protein expression, including the proteins reproducibly expressed within subgroups and those unique to individual lymphomas, undoubtedly are reflected in the different clinical outcomes seen within these apparently homogeneous B-cell lymphoma subgroups. Identification of specific protein profiles associated with different clinical outcomes would be of great value in therapeutic decision making for patients with these lymphomas. Our study also provides potential insight into the mechanism of FL progression. The function of low-molecularweight proteins in lymphoma pathogenesis is largely unknown owing to limitations of 2D gel electrophoresis. 17 However, many low-molecular-weight proteins have been shown to have important roles in cell cycle regulation, cell proliferation and differentiation, apoptosis, regulation of signaling pathways, and DNA repair. SELDI-TOF is particularly advantageous for detecting low-molecular-weight proteins and peptides. 17, 18 The most stable and reproducible protein expression spectra were seen in the mass range of 2,000 to 15,000 d.
Our study identified histone H4 as a potential candidate protein involved in FL transformation. Differential acetylationdeacetylation of histones has an important regulatory role in the development of cancer. Inhibitors of histone deactylase provide a potential therapy for a number of subtypes of malignant lymphoma. 19, 20 Some genetic alterations commonly seen in B-cell lymphomas involve the histone H4 gene at 6p21, providing support for the potential importance of this protein. The recurrent t(3;6)(q27;p21) in B-cell lymphomas results in a fusion of the histone H4 and bcl-6 genes. 21 However, the specific role of histone H4 in follicular transformation remains to be seen.
Our results demonstrate the potential for use of proteomics in the evaluation of lymphomas, which likely will provide another way to discover the crucial proteins and protein ❚Figure 8 ❚ One-dimensional tris-tricine gel electrophoresis of grade 1 (G1) and grade 3 (G3) follicular lymphoma (FL). The indicated band was identified using matrix-assisted laser desorption/ionization mass spectrometry/mass spectrometry as histone H4. MW, molecular weight.
